#1 Clinical Trials Search in Europe

Dyp688

A groundbreaking clinical trial is underway to investigate the potential of DYP688, a new drug designed to treat metastatic uveal melanoma (MUM) and other melanomas with specific genetic mutations. This study aims to evaluate the safety, tolerability, and effectiveness of DYP688 in patients with these challenging forms of cancer. The trial consists of two phases and includes different patient groups, offering hope for those who have limited treatment options.

Table of Contents

What is DYP688?

DYP688 is a new drug that is currently being studied as a potential treatment for certain types of melanoma, a serious form of skin cancer[1]. It is being developed as a single agent, which means it is designed to be used on its own, without combining it with other medications. This drug is still in the early stages of research, and scientists are working to understand how it works and how it might help patients with specific types of melanoma.

What Conditions Does DYP688 Target?

DYP688 is primarily being studied for the treatment of metastatic uveal melanoma (MUM)[1]. Uveal melanoma is a rare type of eye cancer that starts in the uvea, the middle layer of the eye. When this cancer spreads to other parts of the body, it’s called metastatic uveal melanoma. Additionally, the drug is being investigated for other melanomas that have specific genetic changes called GNAQ/11 mutations. These mutations are often found in uveal melanoma but can also occur in other types of melanoma.

The Clinical Trial of DYP688

A clinical trial is currently underway to study DYP688[1]. This trial is described as a “First in Human” (FIH) study, which means it’s the first time this drug is being tested in people. The main goals of this trial are to:

  • Determine if DYP688 is safe for patients to take
  • Find out how well patients tolerate the drug
  • See if the drug shows any anti-tumor activity (ability to shrink or stop the growth of tumors)

Phases of the Clinical Trial

The clinical trial for DYP688 is divided into two main parts[1]:

  1. Phase I (Dose Escalation): This initial phase aims to find the right dose of DYP688. Researchers will gradually increase the dose to determine the maximum tolerated dose (MTD) and/or the recommended dose (RD) for future studies.
  2. Phase II: Once the appropriate dose is determined, the study will move to Phase II. This phase will further evaluate the drug’s effectiveness and safety in specific groups of patients.

Safety and Efficacy Assessments

Throughout the clinical trial, researchers will closely monitor patients to assess the safety and effectiveness of DYP688[1]. Some key aspects they’ll be looking at include:

  • Safety: They will track any side effects or adverse events that patients experience while taking the drug.
  • Tolerability: Researchers will monitor how well patients can tolerate the drug, including any need for dose adjustments or treatment interruptions.
  • Anti-tumor activity: They will measure how well the drug works against the cancer, looking at factors like tumor shrinkage and how long the drug keeps the cancer under control.
  • Pharmacokinetics: This involves studying how the drug moves through the body, including how quickly it’s absorbed, distributed, and eliminated.
  • Immunogenicity: Researchers will check if the patient’s immune system develops antibodies against the drug, which could potentially affect its effectiveness.

Patient Groups in the Study

The clinical trial includes several different groups of patients[1]:

  • Phase I: Patients with metastatic uveal melanoma or other melanomas with GNAQ/11 mutations
  • Phase II:
    • Patients with metastatic uveal melanoma who have not been treated with a drug called tebentafusp
    • Patients with metastatic uveal melanoma who have previously been treated with tebentafusp
    • Potentially, a group of patients with non-uveal melanomas that have GNAQ/11 mutations

Potential Benefits of DYP688

While it’s important to remember that DYP688 is still in the early stages of research, the hope is that it could provide several potential benefits for patients[1]:

  • A new treatment option for metastatic uveal melanoma, which currently has limited effective treatments
  • Potential effectiveness against other types of melanoma with specific genetic mutations
  • Possible improvement in overall survival for patients with these difficult-to-treat cancers

As the clinical trial progresses, more information will become available about the effectiveness and safety of DYP688. Patients interested in this treatment should discuss it with their healthcare providers to understand if it might be an appropriate option for them.

Aspect Details
Drug Name DYP688
Study Type Phase I/II, open-label, multi-center
Target Conditions Metastatic Uveal Melanoma (MUM) and other GNAQ/11 mutant melanomas
Study Phases Phase I: Dose escalation, Phase II: Efficacy evaluation
Patient Groups Tebentafusp-naive, Tebentafusp pre-treated, Non-uveal melanoma (optional)
Primary Outcomes Safety, tolerability, and overall response rate
Secondary Outcomes Pharmacokinetics, immunogenicity, duration of response, progression-free survival, disease control rate, overall survival

FAQ

  • What is DYP688? DYP688 is a new drug being studied for the treatment of metastatic uveal melanoma and other melanomas with GNAQ/11 mutations. It is being tested as a single agent in a clinical trial to determine its safety and effectiveness.
  • What types of patients are included in this clinical trial? The trial includes patients with metastatic uveal melanoma (MUM) and other melanomas that have GNAQ/11 mutations. In the second phase, there are separate groups for patients who have and have not been previously treated with tebentafusp, another medication for uveal melanoma.
  • What are the phases of this clinical trial? The trial has two main parts: Phase I is a dose escalation study to determine the safe and effective dose of DYP688. Phase II will further evaluate the drug's effectiveness in different patient groups, including those with and without prior tebentafusp treatment.
  • What are the main goals of this clinical trial? The main goals are to assess the safety and tolerability of DYP688, determine the appropriate dose, and evaluate its anti-tumor activity in patients with metastatic uveal melanoma and other GNAQ/11 mutant melanomas.
  • How will the effectiveness of DYP688 be measured? The effectiveness will be measured through various outcomes, including overall response rate (ORR), duration of response (DoR), progression-free survival (PFS), and overall survival (OS). These measurements help determine how well the drug works in shrinking tumors and improving patient outcomes.

Ongoing Clinical Trials on Dyp688

  • Study of DYP688 for Patients with Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands Spain

Glossary

  • Metastatic Uveal Melanoma (MUM): A type of eye cancer that has spread from the uvea (the colored part of the eye) to other parts of the body.
  • GNAQ/11 Mutations: Specific genetic changes found in some melanomas, particularly uveal melanomas, that affect the GNAQ or GNA11 genes.
  • First in Human (FIH): The first time a new drug is tested in human subjects, typically in a small group of people.
  • Dose Escalation: A process in clinical trials where the dose of a drug is gradually increased to find the safest and most effective dose.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Recommended Dose (RD): The dose of a drug recommended for further study or use based on clinical trial results.
  • Tebentafusp: A medication used to treat metastatic uveal melanoma.
  • Dose Limiting Toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug being tested.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Immunogenicity (IG): The ability of a substance to provoke an immune response in the body.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DoR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Progression Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Disease Control Rate (DCR): The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response, and stable disease.
  • Overall Survival (OS): The length of time from the start of treatment that patients diagnosed with the disease are still alive.

References

  1. https://clinicaltrials.gov/study/NCT05415072